This article is more than 5 years old. Information may no longer be current.

Bausch + Lomb licenses technology to treat ocular redness

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bausch + Lomb has entered into an exclusive global license agreement with Eye Therapies regarding a new platform technology to relieve ocular redness, according to a company news release.

The platform, developed in collaboration with Ora, uses a low dose of brimonidine, the release said.

“The new low-dose brimonidine formulation appears to provide greater microvessel constriction at mucosal surfaces and is thought to retain more optimal blood flow from larger feeder vessels,” Mark B. Abelson, MD, CM, FRCS, FARVO, clinical professor of ophthalmology at Harvard Medical School and senior clinical scientist at Schepens Eye Research Institute, said in the release.

A phase 2 study of the technology resulted in clinician assessments and patient reports of reduced ocular redness, according to the release. There was no rebound vasoconstriction.

The study showed onset of action within 5 minutes and a duration of effect of at least 4 hours, with no serious adverse events, the release said.